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SHORT COMMUNICATION
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Renal failure occurs in about 50% of cases of myeloma and
may be a presenting feature of the disease. It is known to be
a poor prognostic sign, with median survival of 13 months
(MRC, 1984) or less (Cavo, 1986) compared to 30-36
months for myeloma as a whole (Editorial, 1988). In about
half the patients renal failure is reversible following initial
treatment (Pozzi, 1986; Rota, 1987) but the management of
such patients frequently raises problems. For example, the
administration ofchemotherapy can be difficult; conventional
treatment with melphalan requires careful dose adjustments
to avoid severe haematological toxicity on the one hand and
under-treating the disease on the other.
Infused vincristine and adriamycin with high dose steroids
in the form of either dexamethasone (Barlogie, 1984) or
methylprednisolone (Forgeson, 1988), is recognised to be
effective therapy in myeloma and to be capable of causing a
rapid reduction in paraprotein in responding patients. In
view of these findings we have evaluated the use of such
treatment in eight patients with myeloma complicated by
renal failure which had not responded to rehydration. The
purpose of the study was to establish, first, whether this
treatment is effective therapy in this poor prognosis group
and, second, whether it can be given with acceptable toxicity.
The eight patients, mean age 62, range 49-77, all had
myeloma as defined by widely accepted criteria (MRC, 1980)
and renal failure from the time of presentation (median
creatinine 496tsmolI1, range 212-1,170). Four had renal
biopsies which all showed features of myeloma kidney and
four required urgent dialysis at presentation. Four patients
had been given other chemotherapy before receiving VAMP/
VAD (Table I) but only one had responded to this.
The chemotherapy given was as follows. VAMP: vincris-
tine 0.4mg and adriamycin (doxorubicin) 9mgm-2 i.v. in
1 litre of 5% dextrose over 24h and methylprednisolone
I g m-2 i.v. all given daily for 4 days. VAD: vincristine
0.4mg and adriamycin 9mgm2 i.v. in 1 litre of 5% dex-
trose over 24h daily for 4 days and dexamethasone
40mgday-' orally on days 1-4, 9-12 and 17-20.
Both regimens were repeated every 3-4 weeks. All intra-
venous drugs were given by peripheral venous cannulae. Six
patients had treatment with VAMP alone and two had both
VAD and VAMP.
The VAD regime was used initially but later changed to
VAMP after experience suggested that it was better tolerated
and more easily administered. All patients responded as
shown by a median reduction in paraprotein concentration of
75% (range 54-98%) (P<0.05, Wilcoxson rank sum test)
(Table II). Three of the four patients dependent on dialysis at
the time of treatment recovered sufficient renal function for
dialysis to be withdrawn. Renal function improved or
stabilised in three of the other four patients and deteriorated
in one during the initial VAD/VAMP treatment. Only one of
these patients (with amyloidosis) subsequently required
maintenance dialysis.
The first five patients treated were given VAD/VAMP
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therapy until plateau was reached. However, when treatment
was stopped they relapsed quickly with a median plateau
duration of only 4 months (range 2-9 months). Four of the
eight patients are still alive and the median survival for the
whole group from diagnosis ofmyeloma is at least 25 months
and at least 22 months from VAMP/VAD treatment.
Serious toxicity (septicaemia and fluid overload) developed
in only three patients, two of whom subsequently had their
doses of adriamycin and methylprednisolone reduced by
50%. No other dose reductions were necessary.
The treatment of myeloma complicated by renal failure
remains problematic and the use of melphalan in this situa-
tion is frequently difficult (Rota, 1987) since it is mainly
excreted by the kidney. In our experience, despite dose reduc-
tions the effects are unpredictable and some patients become
severely neutropenic. In this study we have investigated the
efficacy and toxicity of regimens containing vincristine,
adriamycin and high dose steroids as both first line and
second line therapy. The treatment was chosen because excre-
tion of the drugs involved is predominantly non-renal and we
were therefore able to give full doses to the majority of
patients. In addition, since the response to VAMP or VAD is
prompt (Barlogie, 1984), we reasoned that a rapid reduction
in urinary light chain excretion might enhance the recovery
of reversible renal tubular damage.
All patients responded with a reduction in paraprotein of
more than 50% (median 75%). However, they showed a
tendency to relapse quickly when therapy was discontinued, a
phenomenon which has been noted by others (Gaminara,
1988). Because of this we have recently started treating
patients with consolidation/maintenance chemotherapy but
follow-up is not yet long enough to assess the effect.
There was a major improvement in renal function in half
the patients and deterioration in only one, which is consistent
with other published data (Rota, 1987). Several series of
patients with renal failure in myeloma have been reported.
Cavo (1986) described 26 patients who had renal failure at
diagnosis of myeloma and found a median survival of only 4
months. The median survival from myeloma diagnosis for
patients with renal failure in the fourth MRC trial was less
than 13 months (MRC, 1984). Two other series (Pozzi, 1986;
Rota, 1987) have shown similar survival duration. In the
present study, the median survival for the whole group from
diagnosis of myeloma is at least 25 months, and at least 22
months following VAMP/VAD treatment. Our data demon-
strate that VAMP is effective treatment in this situation and
suggest that it may be an improvement on conventional
regimens containing melphalan although the number of
patients involved is small.
The favourable results obtained from using VAMP/VAD
in high risk patients were achieved with side-effects which
were not noticeably different from those seen in patients
without renal failure (Barlogie, 1984; Forgeson, 1988).
Serious side-effects developed in only three patients and there
were no treatment-related deaths.
In conclusion, this study has shown that VAMP can be
safely used for myeloma complicated by renal failure and
may be considered as a suitable first line regime for use in
this situation.
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Table I Previous chemotherapy, VAMP/VAD treatment and toxicity
Time of VAMP Initial
Previous treatment after VAMPIVAD
Patient chemotherapy diagnosis treatment Toxicity
1 ABCM 15 months VAD x 3 Extravasation, hyperglycaemia
C weekly
2 melphalan 12 months VAD x 3
C weekly
3 - immediate VAMP x 4
4 M&P 6 months VAMP x 4
5 M&P 15 months VAMP x 3 Neutropenia, septicaemia, fluid overload
6 - immediate VAMP x 5
7 - immediate VAMP x 3 Neutropenia, septicaemia, steroid
withdrawal
8 - immediate VAMP x 2 Fluid overload
C, weekly cyclophosphamide and prednisolone; ABCM, adriamycin, BCNU, cyclophosphamide and
melphalan; M&P, melphalan and prednisolone.
Table II Response, further treatment and survival
Paraprotein (g 1-') Creatinine
Plasma Urine (ptmol1-') Survival since
Further diagnosis
Patient Pre Post Pre Post Pre Post treatment (months)
1 84 36 0.56 0.27 362 300 VAMP x 5 50
2 22 5.0 0.45 2.8 201 288 VAMP x 1 38(CAPD)
3 53 20.5 1.33 0.03 1160 144 C&M 21 +
4 4.5 2.5 8.5 2.3 676 768 - 30 + (HD)
5 - - 0.62 0.12 563 273 VAMP x 4 25
6 2.0 2.0 0.79 0.14 423 282 - 25 +
7 16 5.5 0.27 0.08 570 113 C&M 17 +
8 5.5 2.5 * 409 680 ABCM 6
HD, long-term haemodialysis; CAPD, long-term continuous ambulatory peritoneal dialysis; C&M, oral
cyclophosphamide and melphalan; ABCM, adriamycin, BCNU, cyclophosphamide and melphalan. * Data
not available.
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